Fatal agranulocytosis associated with Metamizole treatment in a 16-year-old girl

Main Article Content

Packo Dieu-le-veut Saint-Cyr Sylvestre*
Nanho Danho Clotaire
N’dhatz Comoe Emeraude
Boidy Kouakou
Camengo Police Serge Magloire
Diakité Mamady
Mbelesso Pascal
Koffi Kouassi Gustave

Abstract

Agranulocytosis is one of the common reasons of consultation in hematology. It’s life-threatening because of an infection risk. The metamizole is a drug, known for its potential rare danger of inducing a severe agranulocytosis. However, it remains widely used because of its beneficial effect analgesic and antipyretic. We report in this study, a case of a girl who was 16 years old, referred for severe agranulocytosis, and appeared two weeks after treatment with Novalgin. The clinico-biological symptoms were dominated by Streptococcal septicemia with an infectious pulmonary and digestive focus. The blood cell count confirmed a severe agranulocytosis with total disappearance of neutrophils. Despite broad-spectrum antibiotic therapy and stimulation with hematopoietic growth factor, the clinical evolution was fatal in the short term. What motivates us to add this case to those of the literature in order to remind practitioners about the danger of this drug, and to promote has doubled of vigilance during use.

Article Details

Saint-Cyr Sylvestre, P. D.- le- veut, Clotaire, N. D., Emeraude, N. C., Kouakou, B., Serge Magloire, C. P., Mamady, D., … Gustave, K. K. (2019). Fatal agranulocytosis associated with Metamizole treatment in a 16-year-old girl. Archives of Case Reports, 3(1), 035–037. https://doi.org/10.29328/journal.acr.1001019
Case Reports

Copyright (c) 2019 Saint-Cyr Sylvestre PD, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.

License: Copyright © 2017 - 2025 | Creative Commons License Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.

With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.

Compliance 'CC BY' license helps in:

Permission to read and download
Permission to display in a repository
Permission to translate
Commercial uses of manuscript

'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license. 

Fillet, Georges. Agranulocytose médicamenteuse. Méd et hyg. 1984; 42: 2533-2541.

Bassetti S. Absence of evidence is not evidence of absence. In Forum Médical Suisse 2017; 17: 1059-1060.

Garcia S, Canionero M, Lopes G. Dipyrone-induced granulocytopenia: a case for awareness. Pharmacotherapy. 2006; 26:440-442. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16503727

Haschke M, Liechti ME. Métamizole: bénéfices et risques par rapport au paracétamol et aux AINS. Forum Med Suisse. 2017; 17:1067–1073.

Gupta BMD. Rapport sur un cas mortel d'agranulocytose. Ind Med Gaz. 1936; 71: 589-590. PubMed PMID: 29013107; PubMed Central PMCID: PMC5170691.

Rollason V, Desmeules JA. Use of metamizole in children and the risk of agranulocytosis. Is the benefit worth the risk?. Eur J Anaesthesiol. 2015; 32:837-848. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26509242

Benjamin J, Biederman J. Agranulocytic leukopenia induced by a drug related to aminopyrine. Journ Am Med. 1936; 107:493-494.

Fieler M, Eich C, Becke K, Badelt G, Leimkühler K, et al. Metamizole for postoperative pain therapy in 1177 children. A prospective, multicentre, observational, post authorisation safety study. Eur J Anaesthesiol 2015; 32:839-843. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26086280

Altman D, Bland J. Absence of evidence is not evidence of absence. Br Med Journ 1995; 311: 485.

Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case–Control Surveillance Study. Eur J Clin Pharmacol 2015; 71:219-227. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25378038

Salama A, Schtz B, Kiefel V, Breithaupt H, Mueller‐Eckhardt C. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989; 72:127-132. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2788011

Paitel JF, Stockemer V, Dorvaux V, Witz F, Guerci A, et al. Agranulocytoses aiguës médicamenteuses. Etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies. Rev méd int. 1995; 16:495-499.